학술논문
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Document Type
Article
Author
Ramgopal, M.N.; Castagna, A.; Cazanave, C.; Diaz-Brito, V.; Dretler, R.; Oka, S.; Osiyemi, O.; Walmsley, S.; Sims, J.; Di Perri, G.; Sutton, K.; Sutherland-Phillips, D.; Latham, C.L.; D'Amico, R.; Patel, P.; Spreen, W.R.; Garges, H.P.; Smith, K.; Berni, A.; Zhang, F.; Pascual Bernáldez, M.; Van Solingen-Ristea, R.; Van Eygen, V.; Chounta, V.; van Wyk, J.
Source
In: The Lancet HIV . (The Lancet HIV, September 2023, 10(9):e566-e577)
Subject
Language
English
ISSN
23523018